Overview of Dr. Iyer
Dr. Gopakumar Iyer is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Vanderbilt University School of Medicine and has been in practice 14 years. He is one of 503 doctors at Memorial Sloan Kettering Cancer Center and one of 87 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
353 East 68th Street
New York, NY 10065
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of MichiganResidency, Internal Medicine, 2004 - 2007
Forest Park HospitalInternship, Transitional Year, 2003 - 2004
Vanderbilt University School of MedicineClass of 2003
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2007 - 2025
MI State Medical License 2004 - 2011
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer Start of enrollment: 2022 Feb 17
Roles: Contact
- Gemcitabine and Cisplatin Without Cystectomy for Patients with Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations Start of enrollment: 2018 Dec 10
Roles: Contact, Study Chair, Principal Investigator
- Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) Start of enrollment: 2022 Feb 15
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters.Naitao Wang, Mohini R Pachai, Dan Li, Cindy J Lee, Sarah Warda
Nature Genetics. 2025-01-01 - 4 citationsFirst-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.Filip Janku, Tae Min Kim, Gopakumar Iyer, Anna Spreafico, Elena Elez
European Journal of Cancer. 2024-01-01 - 4 citationsMolecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Gr...Rachel N Grisham, Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher
Clinical Cancer Research. 2023-10-13
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
